Kiora CDO granted stock options and RSUs

Kiora Pharmaceuticals Chief Development Officer Eric Joseph Daniels reported new equity awards.

Rhea-AI Filing Summary

Kiora Pharmaceuticals Chief Development Officer Eric Joseph Daniels reported new equity awards. He received a stock option for 13,067 shares of common stock at an exercise price of $1.98 per share, and a grant of 6,533 shares of restricted stock, both under the 2024 Equity Incentive Plan.

The restricted stock vests in three equal installments on April 1, 2027, April 1, 2028, and April 1, 2029, subject to continued service. The option vests one-third on April 1, 2027, with the remaining balance vesting monthly over the following two years and expiring on April 1, 2036. After the grants, Daniels directly owns 32,670 common shares.

Insider Trade Summary

Grant/Award: 19,600 shares

Grant/Award 2 txns

Insider Daniels Eric Joseph

Role Chief Development Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	13,067	$0.00	$0.00
Grant/Award	Common Stock	6,533	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 13,067 contracts (Direct); Common Stock — 32,670 shares (Direct)

Footnotes (2)

1. F1. Grant of restricted stock from the Issuer pursuant to the Issuer's 2024 Equity Incentive Plan (the "Plan"). The restrictions will vest as to one-third (1/3) of the shares on each of April 1, 2027, April 1, 2028 and April 1, 2029, subject to the reporting person's continuous service through each such vesting date.
2. F2. The reporting person received an option to purchase Common Stock from the Issuer pursuant to the Plan. The option will become exercisable as to one-third (1/3) of the shares underlying the Option on April 1, 2027, and the remaining balance vests monthly on the first day of each calendar month thereafter for a period of two years, subject to the reporting person's continuous service through each such vesting date.

FAQ

What equity awards did KPRX executive Eric Joseph Daniels receive?

Eric Joseph Daniels received a stock option for 13,067 Kiora Pharmaceuticals shares at an exercise price of $1.98, plus a grant of 6,533 restricted shares. Both awards were issued under the company’s 2024 Equity Incentive Plan as compensation, not open-market purchases.

How do the new stock options for KPRX’s Chief Development Officer vest?

The 13,067-share stock option vests over three years. One-third of the option becomes exercisable on April 1, 2027, with the remaining shares vesting monthly on the first day of each month for two years, subject to Daniels’ continuous service with the company.

What is the vesting schedule for Eric Daniels’ restricted KPRX shares?

The 6,533 restricted Kiora Pharmaceuticals shares vest in three equal installments. One-third vests on April 1, 2027, one-third on April 1, 2028, and the final third on April 1, 2029, assuming Daniels remains in continuous service through each date.

What are Eric Daniels’ KPRX share holdings after these transactions?

Following the reported grants, Eric Joseph Daniels directly holds 32,670 shares of Kiora Pharmaceuticals common stock. He also holds a newly granted option covering 13,067 shares, which begins vesting in 2027 and remains exercisable until its expiration in 2036.

Are Eric Daniels’ KPRX equity awards open-market purchases or compensation grants?

These Kiora Pharmaceuticals transactions are compensation-related grants. Both the 13,067-share stock option and the 6,533 restricted shares were awarded at a price of $0.00 per share under the 2024 Equity Incentive Plan, rather than being bought on the open market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/10/2026 - 04:37 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Daniels Eric Joseph

(Last) (First) (Middle)

C/O KIORA PHARMACEUTICALS, INC.

169 SAXONY RD., SUITE 212

(Street)

ENCINITAS CA 92024

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
KIORA PHARMACEUTICALS INC [ KPRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Development Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/06/2026		A		6,533(1)	A	$0	32,670	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$1.98	03/06/2026		A		13,067		04/01/2027(2)	04/01/2036	Common Stock	13,067	$0	13,067	D

Explanation of Responses:

1. Grant of restricted stock from the Issuer pursuant to the Issuer's 2024 Equity Incentive Plan (the "Plan"). The restrictions will vest as to one-third (1/3) of the shares on each of April 1, 2027, April 1, 2028 and April 1, 2029, subject to the reporting person's continuous service through each such vesting date.

2. The reporting person received an option to purchase Common Stock from the Issuer pursuant to the Plan. The option will become exercisable as to one-third (1/3) of the shares underlying the Option on April 1, 2027, and the remaining balance vests monthly on the first day of each calendar month thereafter for a period of two years, subject to the reporting person's continuous service through each such vesting date.

Remarks:

	/s/ Melissa Tosca, Attorney-in-Fact	03/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.